Literature DB >> 2990514

Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.

E Sachs, A M Di Bisceglie, G M Dusheiko, E Song, S F Lyons, B D Schoub, M C Kew.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2990514      PMCID： PMC1977152          DOI： 10.1038/bjc.1985.156

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  4 in total

1.  Tumorigenicity and interferon properties of the PLC/PRF/5 human hepatoma cell line.

Authors:  J Desmyter; G De Groote; M B Ray; A F Bradburne; V Desmet; P De Somer; J Alexander
Journal:  Prog Med Virol       Date:  1981

Review 2.  The clinical value of interferons as antitumor agents.

Authors:  A Billiau
Journal:  Eur J Cancer Clin Oncol       Date:  1981-09

Review 3.  The hepatitis-B virus and hepatocellular carcinoma.

Authors:  M C Kew
Journal:  Semin Liver Dis       Date:  1981-02       Impact factor: 6.115

4.  Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus.

Authors:  D Shouval; B Rager-Zisman; P Quan; D A Shafritz; B R Bloom; L M Reid
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808
  4 in total
  9 in total

Review 1.  Hepatocellular carcinoma.

Authors:  S Badvie
Journal:  Postgrad Med J       Date:  2000-01       Impact factor: 2.401

Review 2.  Practical considerations in the treatment of hepatocellular carcinoma.

Authors:  M Colleoni; R A Audisio; F De Braud; N Fazio; G Martinelli; A Goldhirsch
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

3.  Rapid growth of hepatocellular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases.

Authors:  A Onitsuka; N Yamada; H Yasuda; T Miyata; T Kachi
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy.

Authors:  X Cao; J Wang; W Zhang; G Chen; X Kong; K Tani
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results.

Authors:  M Oka; S Hazama; S Yoshino; K Shimoda; M Suzuki; R Shimizu; K Yano; M Nishida; T Suzuki
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

6.  No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.

Authors:  C Bokemeyer; B Kynast; A Harstrick; E Laage; E Schmoll; P von Wussow; H J Schmoll
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  Current treatment modalities for hepatocellular carcinoma.

Authors:  D G Farmer; M H Rosove; A Shaked; R W Busuttil
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

8.  Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha.

Authors:  W C Hung; L Y Chuang
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

9.  Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

Authors:  C L Lai; P C Wu; A S Lok; H J Lin; H Ngan; J Y Lau; H T Chung; M M Ng; E K Yeoh; M Arnold
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.